drugset
drugset / Trial / NCT06717126

A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal Melanoma

NCT06717126 ↗

Phase 2 Active not recruiting 85 enrolled iOnctura
RandomizedParallel-groupOpen-labelTreatment

Summary

The goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing of roginolisib impact quality of life compared to standard treatment?

Timeline

Start
2025-02-27
Primary completion
2027-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject roginolisib Small molecule 40 mg Oral
Subject roginolisib Small molecule 80 mg Oral

Indications

uveal melanoma